We Offer Worldwide Shipping
Login Wishlist

Acetagastrodin

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1263

  • Specification : 98%(HPLC)

  • CAS number : 64291-41-4

  • Formula : C21H26O11

  • Molecular Weight : 454.4

  • PUBCHEM ID : 163043

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1263

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

454.4

Appearance

Botanical Source

Structure Type

Category

SMILES

CC(=O)OCC1C(C(C(C(O1)OC2=CC=C(C=C2)CO)OC(=O)C)OC(=O)C)OC(=O)C

Synonyms

4-Cyanobenzyl alcohol/p-hydroxymethylbenzonitrile/4-hydroxymethylbenzenecarbonitrile/p-cyanobenzyl alcohol/4-(Hydroxymethyl)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside/β-D-Glucopyranoside, 4-(hydroxymethyl)phenyl, tetraacetate

IUPAC Name

[(2R,3R,4S,5R,6S)-3,4,5-triacetyloxy-6-[4-(hydroxymethyl)phenoxy]oxan-2-yl]methyl acetate

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

184.0±23.6 °C

Boiling Point

551.4±50.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

HGUDVDQXCUHOED-YMQHIKHWSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:64291-41-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27650536

Abstract

AIMS:
To investigate the protective effect of acetagastrodin on visual electrophysiology in patients with early-stage diabetes.

METHODS:
A prospective, randomized, controlled, double-blind trial was conducted. Subjects who were randomly assigned to either the treatment group or the control group were orally administered acetagastrodin or placebo, respectively, for 6 months. The quantity, mean amplitude and mean latency of oscillatory potentials (OPs) wavelets at baseline and 6 months were measured on electroretinogram (ERG), in all subjects.

RESULTS:
A total of 92 right eyes in 92 patients with type 2 diabetes, who were diagnosed for the first time, were enrolled. Each group consisted of 46 cases (46 eyes). There was no significant difference in baseline characteristic between treatment and control groups at baseline, but quantity in treatment group was more than that in control group at 6 months (P = 0.001). The mean amplitude of OPs was reduced in the control group 6 months later compared with treatment group (P = 0.001). As to mean latency of OPs, statistical difference was also detectable between the treatment group and control group 6 months later (P < 0.001). No statistical differences were found in hemoglobin between both groups at 6 months (P > 0.05).

CONCLUSIONS:
Electrophysiological changes would go on worsening even hemoglobin was under control during the initial stage of diabetes. Acetagastrodin treatment may be an effective treatment to protect retinal neurons against such functional impairment during the early stages of diabetes.

KEYWORDS

Acetagastrodin; Diabetic retinopathy; Electrophysiology; Neuropathy; Neuroprotection

Title

Acetagastrodin effects on retinal oscillatory potentials in patients during the early stages of diabetes.

Author

Yang X1, Xu J2, Liu J1, Ni N1, Mei Y3, Lei H1, Wang J4, Niu B5.

Publish date

2017 Jan

PMID

2955659

Title

[Influences of acetagastrodin on fetuses of mice and rats].

Author

Xiong JM, Mo YQ, Liang B, Chen ZH, Deng SX.

Publish date

1987 Jan


Description :

Empty ...